Tahara E, Ito H, Taniyama K, Yokozaki H, Hata J
Hum Pathol. 1984 Oct;15(10):957-64. doi: 10.1016/s0046-8177(84)80125-2.
One hundred twenty-six gastric carcinomas (68 advanced cancers and 58 early cancers) were examined immunohistochemically for alpha 1-antitrypsin (AAT), alpha 1-antichymotrypsin (ACT), and alpha 2-macroglobulin (AMG) within tumor cells. The incidence of these three protease inhibitors was markedly higher in advanced than in early cancers, regardless of the histologic type of gastric carcinoma. In advanced cancers the incidence of both AAT and AMG was significantly higher in well-differentiated adenocarcinomas than in poorly differentiated adenocarcinomas, but no difference was observed in the expression of ACT between these two types of advanced carcinomas. Eighty per cent of the AAT-positive advanced carcinomas had ACT, and 40 per cent of these tumors also contained AMG. The two-year survival rates clearly indicated that well-differentiated adenocarcinomas with AAT have worse prognoses than well-differentiated adenocarcinomas without AAT, but there was no relation between the expression of ACT or AMG and prognosis. These results strongly suggest that the presence of protease inhibitors in gastric carcinomas is related to the invasive growth of the tumors and that AAT is a tissue tumor marker of well-differentiated adenocarcinomas of the stomach. It may also serve as a biologic marker of high malignancy in patients with these gastric cancers.
对126例胃癌（68例进展期癌和58例早期癌）的肿瘤细胞进行了α1抗胰蛋白酶（AAT）、α1抗糜蛋白酶（ACT）和α2巨球蛋白（AMG）的免疫组化检查。无论胃癌的组织学类型如何，这三种蛋白酶抑制剂在进展期癌中的发生率均明显高于早期癌。在进展期癌中，高分化腺癌的AAT和AMG发生率均显著高于低分化腺癌，但这两种类型的进展期癌在ACT表达上未观察到差异。80%的AAT阳性进展期癌有ACT表达，其中40%的肿瘤还含有AMG。两年生存率清楚地表明，有AAT的高分化腺癌的预后比无AAT的高分化腺癌差，但ACT或AMG的表达与预后无关。这些结果强烈提示，胃癌中蛋白酶抑制剂的存在与肿瘤的浸润性生长有关，且AAT是胃高分化腺癌的组织肿瘤标志物。它也可能作为这些胃癌患者高恶性的生物学标志物。
